Introduction to Biohealth Capital Region (BHCR) & BioHealth Innovation (BHI)

By Rich Bendis, President and CEO, BHI
July 27th, 2018
Four Seasons Hotel, Washington D.C.
Welcome to the

Our Goal: To become a Top 3 BioHealth Hub by 2023

www.biohealthcapital.com
Top 10 U.S. Biopharma Clusters

Ranking Based on Five Criteria: 2017

1. NIH Funding
2. Venture Capital Funding
3. Patents
4. Lab Space
5. Jobs

1. Boston / Cambridge, MA
2. San Francisco Bay Area
3. New York-New Jersey
4. San Diego
5. Maryland / Virginia / DC Metro
6. Greater Philadelphia
7. Seattle
8. Raleigh-Durham, NC (inc. Research Triangle Park, NC)
9. Los Angeles / Orange County
10. Chicagoland
BHCR News Stories

MedImmune spins out Viela Bio....
“Viela Bio Spins Out of MedImmune; Launches with Up to $250 Million Series A Financing from Investor Consortium Led by Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital”

Benevir....
Montgomery County, Maryland-base BeneVir Biopharm, Inc. to be acquired by Janssen Biotech, Inc. for up to $1.04B”

Deerfield $40 million investment in Dracen....
“Health care-focused Deerfield Management leads Baltimore biotech's $40M round”

Supernus expansion ....
“Supernus To Expand, Will Move From Rockville To Gaithersburg”

Emergent major contract or opens innovation Center in Baltimore....
“Emergent BioSolutions opens expanded East Baltimore vaccine plant”

Precision medicine raises $275 million....
“Precision Medicine Group Raises $275M to Support Biomarker-Guided Drug Development”

Paragon Biosciences expansion....
“Paragon Bioservices Announces New Commercial Manufacturing Facility Expansion”

Sucampo sale ..... 
“Sucampo Pharmaceuticals closes on its $1.2B sale to a U.K. company”
2018 BioHealth Capital Region Forum

1,129 Registrants
50 Sponsors
Top 3 by 2023

www.bhcrforum.com

April 23 + 24, 2018
One MedImmune Way, Gaithersburg, MD 20878

BioHealth Capital Region Forum Growth

Registrants

<table>
<thead>
<tr>
<th>Year</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>610</td>
<td>852</td>
<td>1069</td>
<td>1127</td>
</tr>
</tbody>
</table>

Sponsors

<table>
<thead>
<tr>
<th>Year</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>17</td>
<td>26</td>
<td>37</td>
<td>50</td>
</tr>
</tbody>
</table>

Showcasing accomplishments and opportunities for the BioHealth Capital Region
BHCR Support Organizations

Richard A. Bendis
President /CEO
BHI sources and evaluates market-relevant biohealth intellectual properties, connects the IP with funding, and assists businesses in marketing and growth.

George Davis, CEO
“TEDCO provides framework of knowledge, funding, and networking to support an innovation eco-system that nurtures researchers, entrepreneurs, start-ups, and early stage companies engaged in bringing innovation ideas to market.”

Tami Howie, CEO
“We are a collaborative community that is actively engaged in building strong technology and life science industries by supporting the efforts of our individual members.”

Jeffrey M. Gallagher
CEO
“We fuel the network of leaders that drive bioscience to eradicate disease, save lives, and feed the world…..one innovation at a time.”
BHCR has Several Good Exits

May 2018
BeneVir acquired for $1.04B by Janssen

Apr 2017
Vtesse acquired for $200 million by SUCAMPO

Dec 2017
SUCAMPO acquired for $1.2 billion by Mallinckrodt Pharmaceuticals

Nov 2017
VWR acquired for $6.5 billion by Avantor

Jan 2017
altimmune acquired by PharmAthene

Dec 2017
HARPOON MEDICAL acquired for $250 million by Edwards Lifesciences

47 M&As since 2012
$10.2 billion Total M&A value

18 IPOs since 2012
$28.3 billion Total IPO value
STATE OF VENTURE-BACKED STARTUPS IN HEALTHCARE

Venture Investment in Healthcare in the BHCR

Number of Angel - Series A Deals & Capital Invested in BHCR

**Strong Angel activity**
Active ecosystem of independent angels, angel groups, and angel syndicates that invest in an average of 45 deals per year

**Consistent Series A activity**
Numerous regional and national funders are active in the BHCR for Series A and late-stage venture capital deals

**Growing Gap at Seed Stage Deals**
With an average 15 seed deals per year, strong startups don’t receive funding to conduct necessary experiments for a Series A investment
**Recent Venture Capital Funding in BHCR**

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Funding Raised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arcellx</td>
<td>Raised $26M to date</td>
<td></td>
</tr>
<tr>
<td>Graybug Vision</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $49M</td>
</tr>
<tr>
<td>NextCure</td>
<td>Technology from Yale</td>
<td>Raised $67M</td>
</tr>
<tr>
<td>Sonavex</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $6.6M</td>
</tr>
<tr>
<td>BeneVir</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $154M</td>
</tr>
<tr>
<td>PGD</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $99.3M</td>
</tr>
<tr>
<td>SpringWorks therapeutics</td>
<td>Pfizer spin-out</td>
<td>Raised $103M</td>
</tr>
<tr>
<td>Dracen Pharmaceuticals</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $40M</td>
</tr>
<tr>
<td>Neuraly Inc.</td>
<td>Neurons</td>
<td>Raised $36M</td>
</tr>
<tr>
<td>NexImmune</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $28.2M</td>
</tr>
<tr>
<td>GlycoMimetics, Inc.</td>
<td>Raised $119M to date</td>
<td></td>
</tr>
<tr>
<td>MedImmune/AstraZeneca spin-out</td>
<td>Raised $250M to date</td>
<td></td>
</tr>
<tr>
<td>RegenXBio</td>
<td>Raised $100M to date</td>
<td></td>
</tr>
<tr>
<td>VIELABio</td>
<td>Raised $32.5M to date</td>
<td></td>
</tr>
<tr>
<td>WindMIL Therapeutics</td>
<td>Raised $10M to date</td>
<td></td>
</tr>
</tbody>
</table>
# Biohealth Success in Montgomery County, Maryland

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
<th>Total Funding</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Altimmune</td>
<td>Expansion and merger with PharmAthene</td>
<td></td>
<td>May 2017</td>
</tr>
<tr>
<td>American Gene Technologies</td>
<td>Expansion into new 24,000 sq. ft. laboratory and offices</td>
<td></td>
<td>October 2017</td>
</tr>
<tr>
<td>Applied Biomimetic</td>
<td>Opened up new US HQ and R&amp;D facilities</td>
<td></td>
<td>February 2018</td>
</tr>
<tr>
<td>Arcellx</td>
<td>Raised $26,000,000 Series A</td>
<td></td>
<td>January 2017</td>
</tr>
<tr>
<td>BeneVir</td>
<td>Agreement to be acquired by Janssen for up to $1,040,000,000</td>
<td></td>
<td>May 2018</td>
</tr>
<tr>
<td>Emergent</td>
<td>Market Authorization of BioThrax in European Countries</td>
<td></td>
<td>April 2018</td>
</tr>
<tr>
<td>GlaxoSmithKline Vaccines</td>
<td>650,000 sq. ft. North American Vaccine R&amp;D HQ</td>
<td></td>
<td>2016</td>
</tr>
<tr>
<td>Gilead</td>
<td>Acquired Kite Pharma for $11,900,000,000</td>
<td></td>
<td>August 2017</td>
</tr>
<tr>
<td>Glycomimetics, Inc.</td>
<td>Multiple Phase 3 candidates Sickle Cell, AML, etc.</td>
<td></td>
<td>2018</td>
</tr>
<tr>
<td>Immunomic, Inc.</td>
<td>Upfront for LAMM-1 Vaccine Platform for Allergies</td>
<td></td>
<td>2018</td>
</tr>
<tr>
<td>Intrexon</td>
<td>Total revenues of $221,000,000 21% increase over full year ended 12/31/16</td>
<td></td>
<td>March 2018</td>
</tr>
<tr>
<td>MacroGenics</td>
<td>Expanding manufacturing capacity with new GMP suite</td>
<td></td>
<td>2018</td>
</tr>
<tr>
<td>MedImmune</td>
<td>Spins out 6 molecules into biotech with $250,000,000 VC investment.</td>
<td></td>
<td>February 2018</td>
</tr>
<tr>
<td>Neuraly Inc.</td>
<td>Raised $36,000,000 Series A</td>
<td></td>
<td>July 2018</td>
</tr>
<tr>
<td>NexImmune</td>
<td>$23,000,000 Series A spin-out of Johns Hopkins University</td>
<td></td>
<td>January 2018</td>
</tr>
<tr>
<td>Precision for Medicine</td>
<td>$275,000,000 in new funding</td>
<td></td>
<td>December 2017</td>
</tr>
<tr>
<td>Promayo</td>
<td>$5,990,000 Series A</td>
<td></td>
<td>April 2018</td>
</tr>
<tr>
<td>Qiagen</td>
<td>$50,000,000 Expansion US HQ</td>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>SUCAMPO</td>
<td>Acquired for $1.2 billion by Mallinckrodt Pharmaceuticals</td>
<td></td>
<td>December 2017</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>Expands to 118,000 sq. ft. with 160 new jobs</td>
<td></td>
<td>March 2018</td>
</tr>
<tr>
<td>United Therapeutics Corporation</td>
<td>Acquires SteadyMed in transaction valued at $216,000,000</td>
<td></td>
<td>March 2019</td>
</tr>
<tr>
<td>VielaBio</td>
<td>Raised $250,000,000 Series A spin-out of MedImmune AstraZeneca</td>
<td></td>
<td>May 2018</td>
</tr>
<tr>
<td>Vitesse</td>
<td>Acquired by SUCAMPO</td>
<td></td>
<td>April 2017</td>
</tr>
</tbody>
</table>

---

**Note:** The total funding amounts are approximate and may not reflect the exact figures due to the nature of the information provided.
# BHI Innovation Capital Map

<table>
<thead>
<tr>
<th>Pre-Proof of Concept</th>
<th>Translational Research/Proof of Concept</th>
<th>Proof of Commercial Relevance/Pre-Seed</th>
<th>Seed/Staart-Up</th>
<th>Early Stage</th>
<th>Later Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>$25,000 - $1,500,000 (over 5 yrs)</td>
<td>$15,000 - $750,000 (over 1 yrs)</td>
<td>$15,000 - $1,500,000</td>
<td>$50,000 - $1,500,000</td>
<td>$200,000 - $2,500,000</td>
<td>$2,500,000 +</td>
</tr>
</tbody>
</table>

- NIH R01
- NIH R03
- NIH R21
- Maryland Stem Cell Research Fund (MSCRF)
- SBIR/STTR Grant Phase 1
- NCATS Cures Acceleration Network (CARI)
- Maryland Stem Cell R Fund (MSCRF)
- TEDCO Technology Validation Program - Proof of Concept
- TEDCO Maryland Innovation Initiative - Phase 1
- JHU - Couler Translational Research Partnership
- UVA - Couler Translational Research Corporation
- Maryland Industrial Partnerships (MIPs @ UMD)
- SBIR/STTR Phase 2
- TEDCO Maryland Innovation Initiative - Phase 2
- Maryland Stem Cell Research Fund (MSCRF) - Pre-Clinical
- Virginia Biosciences Health Research Corporation
- Dingman Center Angels (UMD)
- Maryland Momentum Fund
- UVA Seed Fund
- TEDCO Seed Fund
- GT BioSeed Fund
- Baltimore Angels
- New Dominion Angels
- SBIR/STTR Phase 2
- VTC Innovation Fund
- Maryland Venture Fund
- Abell Venture Fund
- Camden Partners Exelixis Fund
- Inova Strategic Investments
- Maryland Venture Fund
- ABS Capital Partners
- Greenspring Associates
- Novak Biddle Venture Partners
- Sterling Venture Partners
- Harbert Venture Partners
- JMI Equity
- New Enterprise Associates (NEA)
- MMG Ventures LLP
- TDF

## Funding Type Key
- Academic
- Private Capital
- Economic Development

## Tax Credits
- Maryland Biotechnology Investor Tax Credit
- Virginia Angel Investor Tax Credit
- Montgomery County Biotechnology Investor Tax Credit
BioHealth Capital Regions Serial Entrepreneurs

Mark P. Klein
- Precision for Medicine, Inc.
- United BioSource Corporation
- Infoscriber Corporation
- U.S. BioServices, Inc.

Ethan D. Leder
- Precision for Medicine, Inc.
- United BioSource Corporation
- U.S. BioServices, Inc.

Rachel King
- GlycoMimetics
- NEA
- Genetic Therapy, Inc.

Michael Richman
- NextCure
- Amplimmune

James S. Gammie, MD
- Correx, Inc.
- Harpoon Medical, Inc.

Martine A. Rothblatt Ph.D., J.D.
- United Therapeutics Corporation
- GeoStar
- SiriusXM Satellite Radio

Murat V. Kalayoglu
- Cartesian Therapeutics
- Topokine Therapeutics
- HealthHonors Corporation

Wendy Perrow
- AsclepiX Therapeutics
- Alba Therapeutics Corporation

Steve Turner
- Protea Biosciences Group, Inc.
- Clinomics BioSciences Inc.
- Quorum Sciences
University Progress

- USM and JHU have had over 52 life science startups in last 18 months, many receiving venture capital, 4.0 billion in research expenditures, 104 licenses executed, $60 million in license income, 1208 patent applications filed 258 Patent’s issued

- USM has created a new $25 million momentum venture fund

- New Bluefield Innovations Fund, operated by Deerfield Management to capitalize $75 million fund to support JHU startups

- UVA entered into partnership with Inova to create a Northern Virginia research and education campus
Regional Initiatives

- Many independent regional initiatives highlighted in this Forum and for first time communication with each other.

- Maryland Life Science Advisory Board implementing recommendations for Governor Hogan.

- Greater Washington Partnership launched as well as Global Cities Export initiative.

- MTC Merger Completed.

- MCEDC and WorkSource Montgomery two new private public partnerships operational.
Unrivaled Research Assets | Unfulfilled Commercial Promise
800+ BioHealth Companies
State of Maryland: Federal & University Resources

- Population: 5.9 million people

- 59 Federal Laboratories, Centers, & Institutes in Maryland

- Maryland Federal R&D investment exceeding $12 billion annually

JHU and USM represent another $3.5 billion in annual R&D
Challenges to Innovation Economy

- Lack of connection of innovation resources
- Lack of an entrepreneurial culture and C-level executives
- Lack of early-stage funding for commercializing technologies
- Lack of spin-offs from federal and university R&D

BHI Value Proposition

- Connect regional innovation assets
- Develop an entrepreneurial talent and support pipeline
- Attract funding for technology commercialization
- Evaluate commercially relevant federal and university technology
BioHealth Innovation is a Regional Innovation Intermediary

A public-private partnership, serving as an innovation intermediary in the BioHealth Capital Region with a mission to:

- Advance local technologies, assets and resources
- Accelerate innovation
- Globally connect sectors, industries, communities, and markets

- Regionally-oriented
- Private-public partnership, 501(c)(3) nonprofit
- BioHealth Innovation Management, a for-profit subsidiary
- Market-driven, private sector-led and funded
- Neither a government initiative, nor a membership organization
Major Regional BioHealth Companies
Public BioHealth Companies Headquartered in the Region

altimmune
CEL SCI
emergent biosolutions
GenVec
GlycoMimetics, Inc.
INTREXON
MACROGENICS
MaxCyte
NEURALSTEM INC
Northwest Biotherapeutics
Novavax
Osiris Therapeutics, Inc.
ReGenX Biosciences
rexahn Pharmaceuticals
SUCAMPO
Supernus Pharmaceuticals
Regional BioHealth Ecosystem Partners

ACADEMIA
- Research/T2
- Lifelong Learning
- Economic Development

INDUSTRY
- Profit
- Process
- Product

GOVERNMENT
- Sustainability
- Infrastructure Support
- Economic Policy

FOUNDATIONS/NGOS
- Economic Growth
- Community Investment
- Regional Collaboration

INSEPARABLE MISSIONS
BHI Partners and Sponsors

Private Sector
- Adventist HealthCare
- AstraZeneca
- avantor
- BD
- Children's National Health System
- Cushman & Wakefield
- Capital Management, LLC
- Deloitte
- DLA Piper
- emergent biosolutions
- Emmes
- EY
- gsk
- IMmunOMic therapeutics
- INOVA
- Kaiser Permanente
- M&T Bank
- MedImmune
- MITRE
- NEA
- Noble Life Sciences
- Northrop Grumman
- Qiagen
- Roche
- SR-one
- TriBridge Partners
- United Solutions
- United Therapeutics Corporation
- Venable
- WGR

Academia
- bwtech@UMC
- FASTFORwARD
- George Mason University
- Johns Hopkins University
- M tech
- University of Maryland
- University of Maryland BlockFyk
- University System of Maryland
- University of Maryland UM Ventures

Government
- EDA
- Frederick
- Maryland Department of Commerce
- NIH
- National Institutes of Health

Non-Government
- EAGB
- Maryland Tech Council
- MBIA
- Montgomery Country Corporation
- Rockville
- VirginiaBio
- WorkSource Montgomery
# BHI Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Abdun-Nabi</td>
<td>CEO Emergent Biosolutions, Inc.</td>
</tr>
<tr>
<td>Richard A. Bendis</td>
<td>President &amp; CEO BioHealth Innovation, Inc.</td>
</tr>
<tr>
<td>Jarrod Borkat</td>
<td>Vice Chairman Partnerships and Collaborations MedImmune</td>
</tr>
<tr>
<td>Robert Caret, Ph.D.</td>
<td>Chancellor University System of Maryland</td>
</tr>
<tr>
<td>Kenneth Carter, Ph.D.</td>
<td>Chairman Noble Life Sciences</td>
</tr>
<tr>
<td>Christopher Callaghan</td>
<td>Group Vice President, Healthcare Banking M&amp;T Bank</td>
</tr>
<tr>
<td>Ronald J. Daniels</td>
<td>President Johns Hopkins University</td>
</tr>
<tr>
<td>Jens Eckstein, Ph.D.</td>
<td>President SR One (GSK)</td>
</tr>
<tr>
<td>William Hearl, Ph.D.</td>
<td>Founder and CEO Immunomic Therapeutics, Inc.</td>
</tr>
<tr>
<td>Ashish K. Kulkarni, Ph.D.</td>
<td>EVP &amp; CTO Avantor</td>
</tr>
<tr>
<td>Dave Lemus (Treasurer)</td>
<td>COO/CFO Proteros Biostuctures GmbH</td>
</tr>
<tr>
<td>Anne S. Lindblad</td>
<td>President &amp; CEO The Emmes Corporation</td>
</tr>
<tr>
<td>Douglas Liu (Chair)</td>
<td>Senior VP of Global Operations Qiagen</td>
</tr>
<tr>
<td>Joel Marcus</td>
<td>Executive Chairman &amp; Founder Alexandria Real Estate Equities, Inc.</td>
</tr>
<tr>
<td>Beth Meagher</td>
<td>Principal Deloitte Consulting LLP</td>
</tr>
<tr>
<td>Charles Morton (Secretary)</td>
<td>Partner Venable LLP</td>
</tr>
<tr>
<td>Robert Silverman</td>
<td>Head Externalized Drug Discovery Partnering, Roche</td>
</tr>
<tr>
<td>David Mott</td>
<td>General Partner New Enterprise Associates</td>
</tr>
<tr>
<td>Kurt Newman, M.D.</td>
<td>President &amp; CEO Children’s National Medical Center</td>
</tr>
<tr>
<td>Lily Qi</td>
<td>Assistant Chief Administrative Officer Montgomery County Government</td>
</tr>
<tr>
<td>John A. Sackett</td>
<td>President Shady Grove Adventist Hospital</td>
</tr>
<tr>
<td>Mike Gill (Ex-Officio)</td>
<td>Secretary of Business &amp; Economic Development, Department of Commerce</td>
</tr>
</tbody>
</table>
BHI Business Model

Research and technologies enter into the pipeline from sources shown on the left and are evaluated by the EIR team. Commercially relevant startups are connected to assistance programs on a case-by-case basis. Once a startup becomes a portfolio company, they gain access to partners and resources.
BHI Technology Focus

- Therapeutics
- Diagnostics
- Medical Devices
- Healthcare Services
- E-Health
- Mobile Health
- Electronic Medical Records
- Health Informatics
- BioHealth Cybersecurity
- Personalized Health
- Convergence
- Research Tools & Reagents
Innovation Paradigm Shift

PROOF OF CONCEPT
(Technological Feasibility)
Laboratory Push
“It Works!”

PROOF OF COMMERCIAL RELEVANCE
(Market Pull)
“It Works To Solve A Problem”
“‘I’ll Buy It’
BHI Commercialization Model

This commercialization model shows the steps and partners that are involved in the BHI commercialization and support process. The process below leads to the creation of new companies, spin-outs and strategic partnerships. BHI connects companies with a network of public, private and academic entities.

Inventions sourced from Universities, Federal Labs, Private R&D, Basic Research, Industry Spin Outs, and Entrepreneurs
NIH Partnership Agreements

NIH Consulting Entrepreneur Services Contract for 6 NIH Entrepreneurs-in-Residence

PIA between BHI and NIH’s Office of Technology Transfer (OTT) that supports the 27 NIH institutes’ 6,000 scientists and $3 billion intramural research in Montgomery County, MD and the Food and Drug Administration to promote and foster cooperative research and accelerate technology commercialization among NIH/FDA, businesses, and universities.
BHI Team

**Rich Bendis**  
Founder & CEO  
BioHealth Innovation  
40+ years experience:  
Innovation America & Innovation Philadelphia,  
Marion Laboratories,  
Continental Healthcare Systems,  
Kimberley Services,  
Texas Instruments,  
Polaroid, Quaker Oats

**Ken Malone, Ph.D.**  
Entrepreneur-in-Residence  
University System of Maryland  
10+ years industry experience  
& co-founded 13+ university spin-outs

**Ethel Rubin, Ph.D.**  
Entrepreneur-in-Residence  
NIH  
10+ years industry experience

**Luis Gutierrez, Ph.D.**  
Entrepreneur-in-Residence  
NIH  
20+ years industry experience:

**Albine Martin, Ph.D.**  
Entrepreneur-in-Residence  
Johns Hopkins University  
30+ years industry experience:

**Stephen Wolpe, Ph.D.**  
Enterprise-in-Residence  
NIH  
25+ years industry experience & as an  
Independent biotechnology consultant

**Anthony Saleh, Ph.D.**  
Associate  
BioHealth Innovation

**Judy Costello**  
Executive Director  
BioHealth Innovation  
25+ years in economic development  
in Northern VA, Washington DC, and MD
BHI Scouting

NIH/Federal Labs

BHI Portfolio

Entrepreneurs

Existing Biohealth Companies

International Soft Landing

Accelerator Companies

Industry Spinouts

Universities

BHI EIR TEAM
BHI Federal Funding Assistance

- $2.5 billion annual United States Government program coordinated by the Small Business Administration provides grants or contracts to small businesses to spur technological innovation
- Grants awarded in 3 phases between $100,000 and $1.5 million
- Non-dilutive

$23.8M Funding awarded | 34 wins out of 63 SBIR and STTR submissions | 53% win rate
BHI Startup Package

Incubation

BioHealth Innovation

Consulting

Deloitte.

Clinical Services

DP Clinical

Accounting

Banking

Intellectual Property

InHouse Patent Counsel

Corporate Legal

VLP

Preclinical Services

VENABLE®

Grant Writing

Reimbursment

JGS GROUP

Scientific Data Management Services

CMTP

BioIT

SoMax Consulting

LARA

Reimbursement Advisory Services

M&T Bank

Grant Writing

ScienceSherpa
LaunchLab I

• Five laboratory/office modules; each approximately 1,200 Rentable Square Feet (RSF)
• Laboratory space includes casework, sink, fume hood, equipment storage, emergency generator capacity, etc.
• Office space includes one furnished office, two workstations and common lobby, pantry, conference rooms, IT closet, autoclave, and glass wash so business can immediately commence

LaunchLab II

• Move-in ready laboratory/office modules; each approximately 1,192 Rentable Square Feet (RSF) with communal services and amenities designed to facilitate collaboration.
• Fully fit out laboratory space including casework, sink, fume hood, equipment storage, and emergency generator capacity.
• Office space includes one furnished office and two workstations.
• Communal space includes reception/lobby area, pantry, conference rooms, IT closet, autoclave, glass wash, ice maker, and freezer storage.
• Services to guide and facilitate the growth of early-stage companies.
• FitLab, Alexandria’s state-of-the-art fitness center, is available to all LaunchLab occupants.
Features:

- Class A office space located in the heart of the bustling Rockville Town Center—with great access to restaurants, nightlife, community events and fitness facilities.
- Flexible one-year lease agreements with 60-day notice terms.
- Shared conference rooms with state-of-the-art audio visual systems, pre-wired offices to accommodate both telephone and broadband internet service, and wireless internet access.
- Access to market research databases provided through partnership with TEDCO to bona fide entrepreneurs and faculty innovators.

25 Companies* | 86 Jobs  

*includes Montgomery County GreenBank
GERMANTOWN
INNOVATION CENTER

20271 Goldenrod Lane, Germantown, MD 20876
Montgomery County Innovation Network Facility
Managed by BioHealth Innovation, Inc. (BHI)

50 Private Offices and Office Suites | 12 Wet labs | 32,000 square feet

Features:

▪ Turnkey office space with fully fitted wet labs, including RO water, emergency power, and fume hoods. Located in the heart of the new Pinkney Innovation Complex at Montgomery College (PIC-MC).
▪ Flexible one-year lease agreements with 60-day notice terms.
▪ Shared conference rooms with state-of-the-art audio visual systems, pre-wired offices to accommodate both telephone and broadband internet service, and wireless internet access.
▪ On-site access to market research databases provided through partnership with TEDCO to bona fide entrepreneurs and faculty innovators.
▪ Access to interns, faculty and state-of-art equipment at BioScience Education enter, Montgomery College

25 Companies | 126 Jobs
BHI International Soft Landing

BHI offers international companies the perfect starting point to create US-based subsidiaries. Soft landing companies are given access to BHI's extensive business resources including Business Development & Sales, Entrepreneurs-in-Residence (EIR), Financial, Grant Writing/SBIR Federal Funding Assistance, Human Resources, Incubation/Site Location, Legal - Corporate & Intellectual Property, Marketing & Promotion, Market Research, Network & Connections, Regulatory & Preclinical /Clinical, and Reimbursement.
Websites, News and More

BHI Website

The BHI website has news, an events calendar, research publications, regional organization feature stories and resources for the biohealth industry.

www.biohealthinnovation.org

BioHealth Capital Region

The BHCR website highlights the region’s biohealth news, stories, trends and events.

www.biohealthcapital.com

BioTalk

Rich Bendis, hosts BioTalk — conversations with some of the most accomplished and exciting business, academic, and government leaders in the biohealth industry.

BHI News

BHI’s weekly e-newsletter highlights the Central Maryland region’s news articles, national biohealth trends and feature stories.

www.biohealthinnovation.org/news

BHCR News

BHCR News is a monthly publication that highlights industry news throughout the region.

www.biohealthcapital.com
A BIG THANK YOU TO
BHI Contact

1 Church Street, Suite 801
Rockville, MD 20850
(301) 637-7950

info@biohealthinnovation.org

www.biohealthinnovation.org